연구성과로 돌아가기
2021 연구자 정보 (140 / 1146)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Seung, Ki-Bae (Seung, KB) |
Catholic Univ Korea, Coll Med, Dept Internal Med, Cardiol Div, 222 Banpo Daero, Seoul 06591, South Korea |
|
|
[JCR상위 4.8] Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention | SCIE | 4.8 | CARDIAC & CARDIOVASCULAR SYSTEMS;PHARMACOLOGY & PHARMACY | myungho@chollian.net;yasuda.satoshi.hp@ncvc.go.jp; | ||
|
Song, Young Bin (Song, YB) |
Sungkyunkwan Univ, Samsung Med Ctr, Heart Vasc Stroke Inst, Dept Internal Med,Sch Med,Div Cardiol, 81 Irwon Ro, Seoul 06351, South Korea |
IYJ-6953-2023 Song, Young Bin |
|
[JCR상위 4.8] Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention | SCIE | 4.8 | CARDIAC & CARDIOVASCULAR SYSTEMS;PHARMACOLOGY & PHARMACY | myungho@chollian.net;yasuda.satoshi.hp@ncvc.go.jp; | ||
|
Stanca, Carmen (Stanca, C) |
NYU Langone Hlth, New York, NY USA |
|
|
[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | ychoi@cymabay.com; | ||
|
Steinberg, Alexandra (Sasha) (Steinberg, A) |
CymaBay Therapeut, Newark, CA USA |
|
|
[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | ychoi@cymabay.com; | ||
|
Sypsa, Vana (Sypsa, V) |
Natl & Kapodistrian Univ Athens, Dept Hyg Epidemiol & Med Stat, Sch Med, Athens, Greece Natl & Kapodistrian Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, Athens, Greece |
A-5082-2008 SYPSA, VANA |
|
[JCR상위 4.8] The artificial intelligence-driven model for prediction of hepatocellular carcinoma development in chronic hepatitis B patients: Derivation and validation using 11, 111 patients from Asian and Caucasian cohorts [JCR상위 5.9] IMPACT OF HBEAG ON HEPATOCELLULAR CARCINOMA RISK DURING ORAL ANTIVIRAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS B |
SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | pindra@empal.com; | ||
|
Tetri, Brent (Tetri, B) |
St Louis Univ, Sch Med, St Louis, MO USA |
|
|
[JCR상위 4.8] ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | jhamilton@arrowheadpharma.com; | ||
|
Thorburn, Douglas (Thorburn, D) |
Royal Free Hosp, London, England |
|
|
[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | ychoi@cymabay.com; | ||
|
Tobias, Hillel (Tobias, H) |
Concorde Med Grp, New York, NY USA |
|
|
[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | ychoi@cymabay.com; | ||
|
Trivedi, Palak (Trivedi, P) |
Univ Hosp Birmingham, Birmingham, W Midlands, England |
|
|
[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | ychoi@cymabay.com; | ||
|
Tsang, Tak Yin Owen (Tsang, TYO) |
Princess Margaret Hosp, Hong Kong, Peoples R China |
AGS-0035-2022 Tsang, Owen |
|
[JCR상위 4.8] Safety, efficacy, and pharmacodynamic (PD) activity of 12 weeks treatment with oral RIG-I agonist, inarigivir (IRIG), plus 48 weeks of tenofovir alafenamide in adult patients with chronic hepatitis B: a phase 2 collaboration study | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | jenny.yang@gilead.com; | ||
|
Vierling, John M. (Vierling, JM) |
Baylor Coll Med, Houston, TX 77030 USA |
|
|
[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | ychoi@cymabay.com; | ||
|
Yang, Jenny (Yang, J) |
Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA |
KCJ-6006-2024 Yang, Jenny |
|
[JCR상위 4.8] Safety, efficacy, and pharmacodynamic (PD) activity of 12 weeks treatment with oral RIG-I agonist, inarigivir (IRIG), plus 48 weeks of tenofovir alafenamide in adult patients with chronic hepatitis B: a phase 2 collaboration study | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | jenny.yang@gilead.com; | ||
|
Yang, Jeong Hoon (Yang, JH) |
Sungkyunkwan Univ, Samsung Med Ctr, Heart Vasc Stroke Inst, Dept Internal Med,Sch Med,Div Cardiol, 81 Irwon Ro, Seoul 06351, South Korea |
|
|
[JCR상위 4.8] Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention | SCIE | 4.8 | CARDIAC & CARDIOVASCULAR SYSTEMS;PHARMACOLOGY & PHARMACY | myungho@chollian.net;yasuda.satoshi.hp@ncvc.go.jp; | ||
|
Yang, Ke (Yang, K) |
CymaBay Therapeut, Newark, CA USA |
|
|
[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies | SCIE | 4.8 | GASTROENTEROLOGY & HEPATOLOGY | ychoi@cymabay.com; | ||
|
Yasuda, Satoshi (Yasuda, S) |
교신저자 | Natl Cerebral & Cardiovasc Ctr, Dept Cardiovasc Med, 6-1 Kishibe Shimmachi, Suita, Osaka 5648565, Japan |
K-5503-2017 Yasuda, Satoshi |
|
[JCR상위 4.8] Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention | SCIE | 4.8 | CARDIAC & CARDIOVASCULAR SYSTEMS;PHARMACOLOGY & PHARMACY | myungho@chollian.net;yasuda.satoshi.hp@ncvc.go.jp; |
페이지 이동: